We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
33 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for NELARABINE-REACH nelarabine 250 mg/50 mL solution for infusion vial.
-
Australian public assessment report (AusPar)Nelarabine-reach (nelarabine) was approved to treat relapsing /refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
-
Prescription medicine decision summaryNelarabine-Reach (nelarabine) is an anti-cancer drug approved for the treatment of relapsing/refractory T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CYCLOPHOSPHAMIDE-REACH cyclophosphamide (as monohydrate) 500 mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CYCLOPHOSPHAMIDE-REACH cyclophosphamide (as monohydrate) 1000 mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CARBOPROST-REACH carboprost (as trometamol) 250 microgram/1mL solution for injection vial.
-
Prescription medicine registrationActive ingredients: nelarabine.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ROMIDEPSIN-REACH 10mg powder for injection vial, and solvent for reconstitution vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FOSAPREPITANT MSN fosaprepitant (as dimeglumine) 150 mg powder for injection vial.
-